Showing results (11-20 of 149) with videos related to
Sort By:
Pageof 15
The Annals of Pharmacotherapy|February 11, 2000
Gender differences in depression and antidepressant pharmacokinetics and adverse eventsE J Frackiewicz, J J Sramek, N R CutlerExpert Opinion on Investigational Drugs|November 4, 2000
Review of the acetylcholinesterase inhibitor galanthamineJ J Sramek, E J Frackiewicz, N R CutlerNeurodegeneration : a Journal for Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration|December 1, 1996
The bridging concept: optimizing dose for phase II/III in Alzheimer's diseaseN R Cutler, J J Sramek, J R KilbornThe Annals of Pharmacotherapy|October 31, 2000
Mild cognitive impairment: emerging therapeuticsJ J Sramek, A E Veroff, N R CutlerClinical Therapeutics|May 1, 1997
Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxietyJ J Sramek, E J Frackiewicz, N R CutlerThe Annals of Pharmacotherapy|May 20, 1999
Cholinesterase inhibitors: a therapeutic strategy for Alzheimer diseaseW J Krall, J J Sramek, N R CutlerLife Sciences|April 21, 1999
NXX-066 in patients with Alzheimer's disease: a bridging studyJ J Sramek, J Hourani, S S Jhee, et al.Journal of Clinical Psychopharmacology|February 1, 1995
Efficacy trial of the 5-HT2 antagonist MDL 11,939 in patients with generalized anxiety disorderJ J Sramek, R E Robinson, A Suri, et al.Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 1, 1995
The utility of salivary amylase as an evaluation of M3 muscarinic agonist activity in Alzheimer's diseaseJ J Sramek, N R Cutler, D J Hurley, et al.Anxiety|January 1, 1994
Pilot study of a CCKB antagonist in patients with panic disorder: preliminary findingsJ J Sramek, M S Kramer, S A Reines, et al.Pageof 15